

S 4467

Protecting Access to Medication Abortion Act

Congress: 117 (2021–2023, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Jun 23, 2022

Current Status: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Latest Action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Jun 23, 2022)

Official Text: <https://www.congress.gov/bill/117th-congress/senate-bill/4467>

Sponsor

Name: Sen. Smith, Tina [D-MN]

Party: Democratic • **State:** MN • **Chamber:** Senate

Cosponsors (10 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Booker, Cory A. [D-NJ]	D · NJ		Jul 11, 2022
Sen. Gillibrand, Kirsten E. [D-NY]	D · NY		Jul 11, 2022
Sen. Hickenlooper, John W. [D-CO]	D · CO		Jul 11, 2022
Sen. Schatz, Brian [D-HI]	D · HI		Jul 11, 2022
Sen. Stabenow, Debbie [D-MI]	D · MI		Jul 11, 2022
Sen. Whitehouse, Sheldon [D-RI]	D · RI		Jul 11, 2022
Sen. Merkley, Jeff [D-OR]	D · OR		Jul 12, 2022
Sen. Kaine, Tim [D-VA]	D · VA		Jul 13, 2022
Sen. Padilla, Alex [D-CA]	D · CA		Jul 13, 2022
Sen. King, Angus S., Jr. [I-ME]	I · ME		Jul 20, 2022

Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	Jun 23, 2022

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
117 HR 8405	Identical bill	Jul 18, 2022: Referred to the House Committee on Energy and Commerce.

Protecting Access to Medication Abortion Act

This bill directs the Food and Drug Administration (FDA) to take steps to allow patients to receive prescriptions for mifepristone, a drug approved by the FDA for medical abortion, via telehealth and for prescriptions for the drug to be filled by mail.

(Mifepristone is subject to a Risk Evaluation and Mitigation Strategy, which imposes various safety-related requirements. During the COVID-19 public health emergency, the FDA suspended enforcement of the current strategy's requirement that the drug must be dispensed in person, and this suspension is still in effect. In December 2021, the FDA stated the data supported modifying the strategy to remove the in-person dispensing requirement.)

Under this bill, the FDA must require the holder of the relevant approved drug application to submit a proposal to modify the strategy. The modification shall (1) remove the in-person dispensing requirement, (2) allow patients to access prescriptions for mifepristone via telehealth, and (3) authorize all pharmacies certified to dispense mifepristone to patients to do so via mail.

Actions Timeline

- **Jun 23, 2022:** Introduced in Senate
- **Jun 23, 2022:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.